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SUMMARY
CpG islands (CGIs) including those at imprinting control regions (ICRs) are protected from de novomethylation in somatic cells. How-
ever, many cancers often exhibit CGI hypermethylation, implying that the machinery is impaired in cancer cells. Here, we conducted a
comprehensive analysis of CGI methylation during somatic cell reprogramming. Although most CGIs remain hypomethylated, a small
subset of CGIs, particularly at several ICRs, was often de novomethylated in reprogrammed pluripotent stem cells (PSCs). Such de novo ICR
methylation was linked with the silencing of reprogramming factors, which occurs at a late stage of reprogramming. The ICR-preferred
CGI hypermethylation was similarly observed in human PSCs. Mechanistically, ablation of Dnmt3a prevented PSCs from de novo ICR
methylation. Notably, the ICR-preferred CGI hypermethylation was observed in pediatric cancers, while adult cancers exhibit
genome-wide CGI hypermethylation. These results may have important implications in the pathogenesis of pediatric cancers and the
application of PSCs.
INTRODUCTION
Pluripotent stem cells (PSCs) have self-renewing activity
and are capable of differentiating into various types of cells,
making them invaluable tools for regenerative medicine
and disease modeling (Stadtfeld and Hochedlinger, 2010;
Yamanaka, 2012). In mice there are two types of pluripo-
tent states, naive and primed. Mouse embryonic stem cells
(ESCs) have naive pluripotency and are derived from inner
cell mass (ICM) of a blastocyst, while mouse epiblast stem
cells (EpiSCs) have primed pluripotency and are derived
from post-implantation epiblast (Nichols and Smith,
2009). Naive and primed PSCs display distinct transcrip-
tional and epigenetic profiles with different developmental
potential (Nichols and Smith, 2009). Notably, naive and
primed PSCs can be established from somatic cells by the
enforced expression of defined transcription factors, such
as Oct4, Sox2, Klf4, and c-Myc (OSKM), under appropriate
culture conditions (induced pluripotent stem cells [iPSCs]
and induced epiblast stem cells [iEpiSCs], respectively)
(Han et al., 2011; Takahashi and Yamanaka, 2006).
Although a number of studies have revealed that iPSCs
and iEpiSCs display shared molecular characteristics with
ESCs and EpiSCs, respectively (Choi et al., 2015; Han
et al., 2011; Maherali et al., 2008; Mikkelsen et al., 2008),
whether induced naive and primed PSCs faithfully recapit-
ulate in vivo pluripotency is unknown.
Genomic imprinting is an essential epigenetic mecha-
nism that controls the monoallelic expression of genes
and is mediated by gamete-derived allele specific DNA
methylation (Ferguson-Smith, 2011). Imprints are estab-
lished exclusively in the male or female germline through
de novo DNA methylation at imprinting control regions
(ICRs) (Bourc’his et al., 2001; Kaneda et al., 2004). Estab-
lished ICRmethylation together with the concomitant un-
methylated state at the other allele is strictly maintained in
somatic cells throughout life (Ferguson-Smith, 2011). Pre-
vious studies demonstrated that Dnmt1, a maintenance
DNAmethyltransferase, together with Uhrf1 is responsible
for the preservation of ICR methylation (Branco et al.,
2008). In contrast, it is not fully understood how unmethy-
lated allele at ICRs are maintained in the unmethylated
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Figure 1. Establishment of Naive and Primed Mouse PSCs and CGI Methylation Analysis
(A) Schematic diagram of the experimental design. Generation of naive and primed PSCs derived directly from embryos or from somatic
cells by reprogramming. Parental alleles can be distinguished by SNPs in (129X1/SvJ 3 MSM/Ms) F1 cells.
(B) Representative images of naive and primed PSCs (ESCs, EpiSCs, iPSCs, iEpiSCs). Scale bars, 100 mm.
(legend continued on next page)
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state. It is known that CpG islands (CGIs) are generally pro-
tected from de novo methylation in somatic cells. Consid-
ering that ICRs often consist of CpG-rich regions including
CGIs, protection from de novo ICR methylation could be
mediated through mechanisms whereby CGIs are pro-
tected from de novoDNAmethylation. Notably, cancer cells
often display abnormal DNA hypermethylation at both
CGIs and ICRs (Sharma et al., 2010), indicating that the
machinery for avoiding de novo CGI methylation is
impaired in cancer cells.
The dysregulation of imprinted genes is implicated in
developmental defects and tumorigenesis (Kato et al.,
1999; Steenman et al., 1994). Indeed, it has been reported
that the dysregulation of imprints compromises the devel-
opmental potential of PSCs (Choi et al., 2017b; Yagi et al.,
2017a). In addition, CGI hypermethylation in cancer cells
are often detectable in tumor-suppressor genes with
concomitant transcriptional silencing, which supports
the notion that de novoCGImethylation plays a role in can-
cer development. It is therefore important to evaluate the
stability of CGI/ICR methylation in PSCs. Several studies
have previously examined the status of imprints in mouse
and human iPSCs (Bar et al., 2017; Johannesson et al.,
2014; Ma et al., 2014; Nazor et al., 2012; Pick et al.,
2009). Differentially methylated regions (DMRs) at the
Dlk1-Dio3 gene cluster are often hypermethylated in
mouse iPSCs, which is linkedwith impaired developmental
potential (Stadtfeld et al., 2010). A large-scale analysis of
allele-specific RNA sequencing (RNA-seq) data revealed
that primed human iPSCs display a higher incidence of
biallelic expression of imprinted genes (Bar et al., 2017).
However, the genome-wide stability of CGI methylation
during the reprogramming process of naive and primed
pluripotency remains to be fully elucidated.
Here we conducted comprehensive methylation analysis
for CGIs and ICRs to understand the epigenetic stability in
naive and primed PSCs. Given that ICR methylation is
highly affected by culture conditions and gender in mouse
PSCs (Choi et al., 2017a; Pasque et al., 2018; Yagi et al.,
2017a, 2017b), in this study we focus on the male reprog-
ramming process under conventional serum-containing
culture conditions. PSCs derived from cells with (129X1/
SvJ3MSM/Ms) F1 genetic background allowed us to inves-
tigate allele-specific DNA methylation at ICRs by single-
nucleotide polymorphisms (SNPs) (Takada et al., 2013;
Yagi et al., 2017a). This effort revealed aberrantmethylation
at several ICRs during the reprogramming of somatic cells
into naive and primed pluripotency. Furthermore, our
data unveiled similar epigenetic aberrations in pediatric
cancers with iPSCs, providing an unappreciated link be-
tween reprogramming and childhood cancer development.
RESULTS
Generation of Naive and PrimedMouse PSCs in which
Parental Alleles Are Distinguishable
To elucidate the stability of CGI methylation during re-
programming into naive and primed PSCs, we generated
iPSCs and iEpiSCs from male mouse embryonic fibroblasts
(MEFs) with piggyBac (PB) vector containing a doxycycline
(Dox)-inducible polycistronic transgene encoding OSKM
(Kim et al., 2016) (Figures 1A–1C, S1A, and S1B). For their
control, we established male ESCs and EpiSCs derived
from embryonic day 3.5 (E3.5) blastocyst and E6.5 post-im-
plantation epiblast, respectively (Figures 1A and 1B). These
cell lines were derived from (129X1/SvJ 3 MSM/Ms) F1
MEFs or embryos in which the parental alleles are distin-
guishable by a large number of SNPs. Early-passage PSCs
(passage 3 [p3] to p4) were used to analyze gene expression
and DNA methylation in this study. RNA-seq analysis
confirmed that the iPSCs and iEpiSCs expressed general
pluripotency-associated genes at levels comparable with
those of control ESCs and EpiSCs (Figure S1C). iPSCs ex-
pressed naive pluripotency-associated genes and iEpiSCs
expressed primed pluripotency-associated genes (Figures
S1D and S1E). The established iPSC and iEpiSC clones ex-
hibited silencing of transgenes even in the presence of
Dox, except for iPSCs 9, 21, and 37, which continuously ex-
pressed mCherry, indicating transgene expression (Figures
(C) An image of mouse partial iPSCs. The mCherry signal represents the expression of the OSKM transgene. The transgene is not silenced in
iPSC 9. Scale bars, 100 mm.
(D) Principal component (PC1 and PC2) analysis of transcriptional profiles by RNA-seq.
(E) Hierarchical clustering analysis of the global DNA methylation status by MethylC-seq.
(F) Box plot of DNA methylation levels at all CGIs in MEFs, ESCs, EpiSCs, iPSCs, and iEpiSCs. Solid lines in each box indicate the median. The
bottom and top of the boxes are lower and upper quartiles, respectively. Whiskers extend to ±1.5 interquartile range (IQR).
(G) Venn diagram of CGIs with increased DNA methylation in PSCs compared with MEFs (DNA methylation difference >0.2). Number in
parentheses indicates the number of CGIs linked to ICR. Note that ICR-linked CGIs are enriched in reprogrammed PSC-specific methylated
CGIs. *p < 0.05, ***p < 0.001, and ****p < 0.0001 (Fisher’s test).
(H) Box plot of DNA methylation levels at unmethylated alleles in ICRs in MEFs, ESCs, EpiSCs, iPSCs, and iEpiSCs. Solid lines in each box
indicate the median. The bottom and top of the boxes are lower and upper quartiles, respectively. Whiskers extend to ±1.5 IQR.
(I) DNA methylation levels at unmethylated alleles in paternal and maternal ICRs in MEFs, ESCs, EpiSCs, iPSCs, and iEpiSCs.
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1C and S1F). The silencing of transgenes is critical for
achieving complete reprogramming to a stable pluripotent
state (Jaenisch and Young, 2008). Consistent with this,
iPSC 9 displayed distinct global transcriptional and meth-
ylome patterns compared with other ESC/iPSC clones
and exhibited a decreased expression level of naive plurip-
otency-associated genes, which reflects the partial reprog-
ramming state (Figures 1D and 1E). Consistent with this,
there were DMRs in partially reprogrammed (partial) iPSC
9 compared with control iPSCs and ESCs (Figure S1G).
Naive PSC lines and primed PSC lines were separately clus-
tered in both transcriptome and DNA methylation
profiling (Figures 1D and 1E). Overall, the established naive
and primed PSC clones by somatic cell reprogramming
harbored shared molecular signatures with naive and
primed control PSC lines, which were directly derived
from embryos.
De Novo DNA Methylation at ICRs in Reprogrammed
PSCs
We next investigated genome-wide CGI methylation pat-
terns by conducting target-captured MethylC sequencing
(MethylC-seq) analysis of various PSC lines. We first
confirmed that MethylC-seq analysis is suitable for the
comprehensive analysis of CGI and ICR methylation since
the probes capture 94.2% CGIs among all mouse CGIs
(21,648 out of 22,948 CGIs). In fact, MethylC-seq analysis
had higher sequencing coverage for CGIs and ICRs than
whole-genome bisulfite sequencing (WGBS), with compa-
rable numbers of sequencing reads (Figure S2A).
MethylC-seq analysis revealed that most CGIs remained
hypomethylated in all PSC lines examined (Figure 1F).
However, a small subset of CGIs exhibited increased
methylation in reprogrammed PSCs compared with
MEFs, which is the origin of the reprogrammed cells
(DNAmethylation difference >0.2) (Figure 1G). The major-
ity of CGIs with increased methylation in iPSCs and
iEpiSCs were similarly methylated in ESCs and EpiSCs,
respectively (Figure 1G), which suggests that methylation
at these CGIs is cell-type-related methylation in PSCs.
Notably, we also observed iPSC/iEpiSC-specific CGI
methylation (Figure 1G), suggesting that such CGImethyl-
ation is associated with the reprogramming. The reprog-
ramming-associated CGI methylation was observed in
various genetic elements (Figure S2B). Of particular inter-
est, CGIs linked to ICRs (n = 27) were significantly enriched
within CGIs with reprogramming-associated methylation
in most reprogrammed PSC clones (p < 0.05 in iPSC 1,
p < 0.001 in iPSC 7, p = 0.05466 in iPSC 13, p < 0.0001 in
iEpiSC B1, and p < 0.0001 in iEpiSC F1, Fisher’s test) (Fig-
ure 1G). Indeed, 9 out of 27 ICR-linked CGIs exhibited
methylation in iEpiSC F1, and 8 of the 9 ICR-linked CGIs
werenotmethylated in embryo-derived EpiSCs (Figure 1G),
indicating that ICRmethylation is closely related to reprog-
ramming. The comprehensive allele-specific analysis for
ICR methylation further confirmed that unmethylated al-
leles at ICRs were frequently de novomethylated in reprog-
rammed PSCs, a feature especially pronounced in iEpiSCs
(Figure 1H). The unmethylated alleles of paternally im-
printed ICRs (H19 DMR and Dlk1-Gtl2 DMR) were heavily
methylated in both iPSCs and iEpiSCs, whereas maternally
imprinted ICRs (e.g., Nap1l5DMR, Kcnq1ot1 DMR, Trappc9
DMR) were often de novomethylated in iEpiSCs (Figure 1I).
De Novo DNA Methylation at Paternal ICRs during
Reprogramming
We next generated heatmaps and dot plots showing
methylation levels and allelic methylation patterns at
ICRs (Figures 2A and 2B). We confirmed that control
MEFs retainmonoallelic ICRmethylation patterns. Consis-
tent with this, the total ICR methylation level in MEFs ex-
hibited approximately 50% as in vivo tissues (Figures 2A,
2B, and S2C), except for partial gain of methylation at a
part of Zac1 DMR and Dlk1-Gtl2 DMR (Figures 2A, 2B,
and S2D). In mice, there are three paternal imprinted loci
(Dlk1-Gtl2 DMR, H19 DMR, and Rasgrf1 DMR). De novo
methylation at Dlk1-Gtl2 DMR was observed not only in
iPSC clones but also in iEpiSC clones, but the loci remained
unmethylated in both ESCs and EpiSCs (Figures 2A and
2B). Consistent with this observation, Meg3 and Rian,
which are regulated by DNA methylation at Dlk1-Dio3
loci, were repressed in iPSCs and iEpiSCs (Figure S2E).
H19 DMR also acquired de novo methylation in reprog-
rammed PSCs, which was further confirmed with multiple
independent PSC clones (Figures 2A, 2B, and S3A). The
unmethylated allele of H19 DMR was similarly methylated
in ESCs to some extent, but not in EpiSCs, indicating
that de novo methylation at H19 DMR takes place during
both the reprogramming and maintenance of naive PSCs
(Figures 2A, 2B, and S3A). We next examined the DNA
methylation status at Rasgrf1 DMR, which was not
captured by MethylC-seq analysis. De novo methylation
Figure 2. DNA Methylation of ICRs during Reprogramming to Naive and Primed Pluripotency in Mice
(A) Heatmap for DNA methylation levels and allelic balance at ICRs in MEFs, ESCs, EpiSCs, iPSCs, and iEpiSCs. The heatmap depicts the
methylation status at CpG sites in which parental alleles have been distinguished. CpG methylation levels and allelic balance for the
methylation are shown for each CpG site. Color scale is shown for DNA methylation levels and allelic balance.
(B) CpG methylation at representative ICRs of MEFs, ESCs, EpiSCs, iPSCs, and iEpiSCs. Each black dot represents a methylation percentage
for each CpG site. Red and blue dots indicate methylation levels at maternal 129 allele and paternal MSM allele, respectively.
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at the unmethylated allele of Rasgrf1 DMR was observed
exclusively in iEpiSCs (Figure S3B), providing additional
evidence that paternally imprinted DMRs are epigeneti-
cally unstable during reprogramming.
De Novo ICR Methylation Is Linked with Silencing of
Exogenous Reprogramming Factors
We found that partial iPSC 9 harbors a smaller number of
methylated CGIs compared with iPSCs (p < 0.0001, Fisher’s
test) (Figure 1G). Notably, iPSC 9 tended to preserve the
monoallelic methylation pattern at ICRs (Figures 1H, 2A,
2B and S3A), which raised the possibility that aberrant
ICR de novo methylation occurred at a late stage of the re-
programming. To examine this possibility, we extended
the culture of iPSC 9 (Figure 3A). We found that a subset
of iPSC 9 cells turned into mCherry-negative cells during
the prolonged culture. Consistent with the fact that the
silencing of reprogramming factors is a critical event for
complete reprogramming, mCherry-negative iPSC 9 cells
expressed higher levels of naive pluripotency genes (Fig-
ure S3C), suggesting that a subset of partial iPSCs converted
into fully reprogrammed iPSCs. Most notably, mCherry-
negative iPSC 9 cells acquired de novo methylation at the
unmethylated allele of H19 DMR and Gtl2 DMR, while
the allele remained unmethylated in mCherry-positive
cells (Figure 3B). This transgene silencing-linked de novo
ICR methylation was similarly observed in partial iPSC
clones 21 and 37 (Figure 3B). These data indicate that de
novo DMR methylation at H19 and Gtl2 is coupled with
the silencing of exogenous reprogramming factors.
De novoDNAMethylation at a Subset ofMaternal ICRs
in Primed PSCs
In contrast to the monoallelic DNAmethylation pattern at
maternally imprinted loci in iPSCs, iEpiSCs exhibited bial-
lelic ICR methylation at a subset of maternal ICRs (e.g.,
Nap1l5, Trappc9), whereas embryo-derived EpiSCs showed
only a modest increase of methylation at these ICRs (Fig-
ures 1I, 2A, and 2B). Hypermethylation at Nap1l5 DMR
was confirmed with multiple iEpiSC clones (Figure S3D).
We also found thatGnas1A ICR is hypomethylated in naive
PSCs (both ESCs and iPSCs) butmaintained in primed PSCs
(both EpiSCs and iEpiSCs) (Figure 2A). Given that Gnas1A
ICR is hypomethylated in ICM of preimplantation em-
bryos (Figure 3C), the decreased Gnas1A ICR methylation
in naive PSCs may reflect the reduced methylation in
ICM. Apart from primary ICRs, secondary DMRs (sDMRs)
acquire parent-of-origin-dependent DNA methylation pat-
terns after implantation. We found that naive PSCs exhibit
reduced methylation levels at Nespas sDMR and Cdkn1c
sDMR, whereas primed PSCs retain monoallelic methyl-
ation (Figure S4A), presumably reflecting the DNAmethyl-
ation status in the in vivo counterpart. Collectively, these
results suggest that the epigenetic integrity of imprinted
DMRs in PSCs is variable and depends on the imprinted
loci and two types of pluripotent states (naive and primed).
Inheritance of De Novo ICR Methylation and Biallelic
Expression of Imprinted Genes after Differentiation
We next examined whether an altered DNA methylation
status at ICRs affects the allelic expression pattern of im-
printed genes. Among maternally imprinted genes, ex-
pressed genes retained monoallelic expression in iEpiSC
lines (Figure S4B), which is consistent with our methylome
data showing that the corresponding ICRs were stably
methylated/unmethylated in reprogrammed PSC lines
(Figure 2A). We noticed that maternally imprinted genes
that acquire de novo ICR methylation (e.g., Nap1l5, Airn)
showed lower or no detectable expression levels in EpiSCs
(data not shown). These results may suggest that imprinted
Figure 3. De Novo ICR Methylation Occurs at the Late Stage of Somatic Cell Reprogramming
(A) Schematic diagram of the experimental design. Partial iPSC 9 cells were passaged three times, and mCherry-negative/-positive cells
(p7) were sorted by fluorescence-activated cell sorting for expression analysis and DNA methylation analysis. Successful sorting was
confirmed after expansion of sorted cells. Scale bars, 100 mm.
(B) DNA methylation analysis at H19 DMR and Gtl2 DMR in mCherry-positive and mCherry-negative iPSCs (clones 9, 21, 37) by conventional
bisulfite sequencing. Open circles represent unmethylated CpGs and closed circles represent methylated CpGs. Crosses indicate undermined
methylation status.
(C) DNA methylation at ICRs in preimplantation embryos. Note that ICMs exhibit reduced methylation levels at Gnas_1A ICR, while
methylation levels are not altered at H19 or Impact ICRs. WGBS data of ICMs were obtained from GEO: GSE84236. MethylC-seq data of MEFs
from our previous study (Yagi et al., 2017a) were used (GEO: GSE84165).
(D) Allelic expression analysis of Igf2 in MEFs and iPSCs. iPSCs exhibit biallelic expression of Igf2, which is consistent with biallelic
methylation at H19 DMR in these cells. Red and blue indicate maternal and paternal alleles, respectively. Numbers in the pie chart display
numbers of the subcloned allele.
(E) Establishment of iPSC-derived secondary MEFs by blastocyst injection. iPSC-derived MEFs were selected by neomycin treatment for
7 days.
(F) DNA methylation analysis of H19 DMR in iPSC-derived MEFs by conventional bisulfite sequencing.
(G) Allelic expression analysis of Igf2 in iPSC-derived MEFs. Biallelic expression of Igf2 is detectable in iPSC-derived MEFs. Red and blue
indicate maternal and paternal alleles, respectively. Numbers in the pie chart display numbers of the subcloned allele.
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genes with lower expression levels are targets of de novo
methylation at maternally imprinted ICRs in iEpiSCs.
It is well known that paternally imprintedH19DMR regu-
lates the monoallelic expression of Igf2 from the paternal
allele (Steenman et al., 1994). Consistent with our observa-
tion that H19 DMR is biallelically methylated in reprog-
rammed PSCs, Igf2 was expressed from both paternal and
maternal alleles in iPSC clones (Figure3D).Aprevious report
suggests that ICR methylation is not recovered in somatic
cell lineages once it is lost in PSCs (Holm et al., 2005). There-
fore, we next investigated whether the acquired de novo ICR
methylation in PSCs is inherited after differentiation. For
this purpose, we injected iPSCs, which harbor de novo
methylation at H19 DMR, into blastocyst and established
iPSC-derived secondary MEFs by neomycin selection (Fig-
ure 3E). Notably, aberrant DNA methylation patterns at
H19 DMR and biallelic expression of Igf2 were detected in
differentiated MEFs (Figures 3F and 3G), indicating that
aberrant de novo ICR methylation was sustained even after
the differentiation of PSCs. This result is consistent with
the silencing ofH19 in ESC nuclei being sustained in differ-
entiated cells afternuclear cloning (Humpherys et al., 2001).
Variable ICR Methylation Status in Human PSCs
To investigate any overlap of aberrant CGI methylation
patterns between mouse and human PSCs, we next
analyzed the genome-wide CGI methylation status in hu-
man primed PSC lines (Nishizawa et al., 2016). Consistent
with our results in mouse primed iEpiSCs, most CGIs were
hypomethylated in human iPSCs (Figure 4A). However, a
subset of imprinted loci was aberrantly methylated in hu-
man iPSCs (hypermethylated DMR, n = 10 loci; hypome-
thylatedDMR, n = 5 loci), whereas cells of origin for human
iPSCs exhibited normal methylation levels (approximately
50%) at the imprinted DMRs (Figures 4B–4D). The aberrant
DMR methylation was not associated with the method
of reprogramming (Figure 4B). Notably, paternally im-
printed genes such as H19, MEG3, and ZDBF2 were
frequently hypermethylated in multiple human PSCs,
which was similarly observed in mouse PSCs (Figure 4E).
These observations are consistent with a recent study
demonstrating that the biallelic expression of imprinted
genes is observed more frequently at paternally imprinted
genes than maternally imprinted genes in human iPSCs
(Bar et al., 2017). As observed in mouse iEpiSCs, several
maternally methylated DMRs (e.g., TRAPPC9, SNRPN,
RB1, and PEG3) were hypermethylated in humanPSCs (Fig-
ure 4E). Conversely, a subset of maternally methylated
DMRs (FAM50B and GNAS) were hypomethylated in hu-
man PSCs (Figure 4D). Importantly, FAM50B and GNAS
are hypomethylated in human preimplantation embryos
(Hanna et al., 2016), which supports the notion that hypo-
methylation at imprinted DMRs in PSCs may reflect the
decreased methylation level of preimplantation embryos.
Dnmt3a Contributes to De Novo ICR Methylation
during Reprogramming in Mice and Humans
During germ cell development, imprinted DMR is de novo
methylated by Dnmt3a in conjunction with Dnmt3l
(Bourc’his et al., 2001;Kaneda et al., 2004). Aprevious study
revealed that Dnmt3a but notDnmt3l is responsible for the
increased methylation at Dlk1-Dio3 imprinted loci during
reprogramming (Stadtfeld et al., 2012). We therefore asked
whether aberrant hypermethylation at other ICRs during
reprogramming is also dependent on Dnmt3a activity.
To test this hypothesis, we analyzed iPSCs derived from
C57/BL6 MEFs lacking Dnmt3a with lentivirus-mediated
Dox-inducible OKSM (Stadtfeld et al., 2012) for ICR
methylation. We observed hypermethylation at H19 DMR
in control iPSCs, affirming that ICR hypermethylation
Figure 4. Variable ICR Methylation Aberrations in Human PSCs
(A) Box plot of DNA methylation levels at all CGIs in human somatic cells and PSCs. Solid lines in each box indicate the median. The bottom
and top of the boxes are lower and upper quartiles, respectively. Whiskers extend to ±1.5 IQR. Infinium 450K data of human somatic cells
and PSCs were obtained from GEO: GSE60821 and GSE60923.
(B) Heatmap for DNA methylation levels at imprinted DMRs in human iPSCs (hiPSCs), human ESCs (hESCs), and various somatic cells of
origin for hiPSCs. Color scale is shown for DNA methylation levels. Infinium 450K data of 35 hiPSC lines (20 male lines and 15 female lines),
4 hESCs, and 16 somatic cells were obtained from GEO: GSE60821 and GSE60923. Names of the hPSC lines are shown at the right of the
panel. Colors depict the methods of reprogramming. HDF, human dermal fibroblasts; CB, cord blood cells; PBMN, peripheral blood
mononuclear cells; DP, dental pulp cells.
(C) List of 36 human imprinted DMRs shown in (A) (Court et al., 2014). Origin (maternal or paternal allele) and timing (germline or
somatic) of methylation are shown for each DMR. IG-DMR (17) is not considered in further analyses because the probes of Infinium 450K
are not designed at IG-DMR.
(D) Difference of median methylation levels at the 35 imprinted DMRs between hiPSCs and somatic cells. The median methylation levels of
the 35 iPSC lines and 16 somatic cells in (B) are compared. Hypermethylated DMRs (false discovery rate [FDR] <0.01, median methylation in
iPSCs >60%) and hypomethylated DMRs (FDR <0.01, median methylation in iPSCs <40%) are shown in pink and blue, respectively.
(E) Box plots of DNA methylation levels at representative paternal and maternal imprinted DMRs in human iPSCs. Solid lines in each box
indicate the median. The bottom and top of the boxes are lower and upper quartiles, respectively. Whiskers extend to ±1.5 IQR. Each color
in the boxes represents a cell of origin. ***p < 0.001 and ****p < 0.0001 (Mann-Whitney U test).
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occurred irrespective of the mouse genetic background or
the PB system. Notably, Dnmt3a-deficient iPSCs displayed
decreased DNA methylation levels at H19 DMR compared
with control cells (Figure 5A). We further established
iEpiSCs from Dnmt3a KO MEFs and examined ICR
methylation (Figure S4C). Dnmt3a knockout (KO) iEpiSCs
exhibited reduced methylation levels at multiple ICRs
compared with control Dnmt3a wild-type (WT) iEpiSCs
(Figures 5B–5D). Of note, methylation levels at multiple
ICRs were close to 50% in Dnmt3a-KO iEpiSCs (Figures
5A–5D). These findings suggest that Dnmt3a plays a domi-
nant role in de novo ICR methylation, although our study
does not exclude the possibility of the contribution of
Dnmt3b. Collectively, Dnmt3a contributes to aberrant de
novo DNA methylation at ICRs during somatic cell reprog-
ramming in mice.
We further tested whether the suppression of DNMT3A
can prevent human iPSCs from hypermethylation at im-
printed DMRs during reprogramming. We generated hu-
man iPSCs from human peripheral blood mononuclear
cells by inducing reprogramming factors with simulta-
neous knockdown of DNMT3A (Figures S4D and S4E). Of
note, DNA methylation levels at MEG3 DMR and IGF2
DMR2 were reduced in DNMT3A KO human iPSCs
compared with control iPSCs (Figure 5E), indicating that
DNMT3A is responsible for hypermethylation at imprinted
DMRs during reprogramming in both mice and humans.
Increased Methylation Levels at a Subset of Imprinted
DMRs in Pediatric Cancers
Increased methylation levels at imprinted DMRs have been
observed in a subset of cancers. Particularly, H19 DMR hy-
permethylation and the concomitant biallelic expression
of IGF2 are frequently detectable in Wilms’ tumors, the
most common human pediatric kidney cancer (Hubertus
et al., 2011; Steenman et al., 1994). We previously demon-
strated that premature termination of in vivo reprogram-
ming in mice leads to the development of cancers (Ohnishi
et al., 2014). Notably, reprogramming-associated kidney
cancers resembled Wilms’ tumor and often harbored
imprinting aberrations, includingH19DMRhypermethyla-
tion (Ohnishi et al., 2014). These results may provide a link
between reprogramming-associated ICR methylation and
epigenetic aberrations in pediatric cancers. Therefore, to
investigate a possible association of aberrant DNA methyl-
ation between Wilms’ tumors and iPSCs, we performed
comprehensive DMR methylation analysis in Wilms’ tu-
mors as well as normal kidney tissues and renal cell carci-
nomas (RCCs), a representativeof adult kidneycancer, using
public datasets. Wilms’ tumors often exhibited increased
methylation levels at imprinted DMRs not only at H19
DMR but also other DMRs, whereas normal kidney samples
and RCCs displayed relatively stable DMR methylation
levels (Figures 6A and 6B). Increased DMR methylation
levels at imprinted loci includingH19DMRwere also detect-
able in neuroblastomas, another type of pediatric cancer
(Figure S4F). Together, these results suggest that de novo
methylation at particular imprinted DMRs is a shared aber-
ration in reprogrammed PSCs and pediatric cancers.
Previous studies demonstrated that CGI hypermethyla-
tion, particularly at CGIs linked to polycomb (PcG) target
genes, is a general feature of epigenetic abnormalities
found in cancers (Feinberg et al., 2006; Schlesinger et al.,
2007; Widschwendter et al., 2007). In contrast, we found
that most CGIs, except for imprinted DMRs, remain hypo-
methylated in iPSCs, which suggests that aberrant CGI
methylation patterns in cancers are distinct from those in
iPSCs. Consistent with previous reports, we detected CGI
hypermethylation in a wide variety of adult cancers and
found it was more prominent at CGIs close to PcG target
genes (Figures 6C–6E). Notably, however, the same analysis
revealed that pediatric cancers as well as iPSCs displayed no
evidence of hypermethylation at global CGIs or even at
PcG target gene-linked CGIs (Figures 6C–6E). Collectively,
our data demonstrated that pediatric cancers harbor similar
patterns of aberrant CGImethylation with iPSCs and high-
lighted the distinct features of epigenetic abnormalities in
pediatric cancers and adult cancers.
DISCUSSION
In the present study,we conducted comprehensivemethyl-
ation analysis for CGIs to elucidate the epigenetic stability
Figure 5. Dnmt3a Mediates Reprogramming-Associated De Novo ICR Methylation in Mice and Humans
(A) DNA methylation status at H19 DMR by conventional bisulfite sequencing in Dnmt3a control (2lox) and KO iPSCs.
(B) DNA methylation status at Nap1l5 DMR and H19 DMR by conventional bisulfite sequencing in Dnmt3a wild-type (WT) and null (KO)
iEpiSCs.
(C) DNA methylation status at paternally methylated DMRs in Dnmt3a wild-type (WT) and null (KO) iEpiSCs. Each bar indicates a CpG site,
and bar height represents methylation percentage (0%–100%) by MethylC-seq.
(D) DNA methylation status at maternally methylated DMRs in Dnmt3a wild-type (WT) and null (KO) iEpiSCs. Each bar indicates a CpG site,
and bar height represents methylation percentage (0%–100%) by MethylC-seq.
(E) DNA methylation status at MEG3 DMR and IGF2 DMR2 by conventional bisulfite sequencing in hiPSCs established with DNMT3A short
hairpin RNA (shRNA) and control shRNA treatment.
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during somatic cell reprogramming into naive and primed
PSCs. This analysis unveiled that most CGIs are precluded
from being methylated, but CGIs linked to ICRs preferen-
tially undergo de novomethylation during reprogramming.
Consistent with this, paternally methylated ICRs often
gained aberrant de novo methylation in both iPSCs and
iEpiSCs. A subset of maternally methylated ICRs (e.g.,
Nap1l5 and Trappc9) was also hypermethylated in primed
iEpiSCs. We also show that human iPSCs exhibit aberrant
CGI methylation at several imprinted DMRs. Notably, the
biallelic expression or silencing of imprinted genes in re-
programmed PSCs are sustained in PSC-derived differenti-
ated cells. Since the proper establishment andmaintenance
of genomic imprints, particularly at H19 DMR (Kono et al.,
2004), are important for normal development inmammals,
our results may have important implications in various ap-
plications of PSCs, including regenerative medicine, drug
screening, and the study of early developmental biology.
Interestingly, de novo ICRmethylationwas not prominent
in partial iPSCs, suggesting that the aberrant ICR methyl-
ation in PSCs was not related to incomplete reprogram-
ming. Notably, de novo ICR methylation occurred in accor-
dance with the silencing of reprogramming factors. A
previous study demonstrated that de novoDNAmethylation
plays a role in PB silencing (Troyanovsky et al., 2016). It is
thus possible that the same machinery is involved in de
novo ICR methylation and PB silencing. Nevertheless,
considering that aberrant DMR hypermethylation is detect-
able in human iPSCs established by various methods, we
propose that the de novo methylation at particular ICRs is
a general phenomenonduring somatic cell reprogramming.
However, it should be noted that there exists clonal varia-
tion in ICR methylation patterns. The clonal variation
may reflect the stochastic nature of the de novomethylation.
Although we demonstrated that Dnmt3a contributes to
the ICR methylation in both mice and humans, the precise
mechanism for de novo ICR methylation remains unclear. A
previous study demonstrated that unmethylated alleles of
imprinted genes are marked with both H3K4me2/3 and
H3K27me3 and exhibit monoallelic bivalent chromatin
when they are transcriptionally inactive (Maupetit-Me-
houas et al., 2016). Of note, a recent study demonstrated
thatDnmt3apreferentially binds tobivalent regions (Manzo
et al., 2017). Collectively, it is possible that bivalent modifi-
cations at the unmethylated allele of imprinted genesmight
bea targetofDnmt3abinding, thusacting as apossible cause
of de novomethylation during reprogramming.
We found that CGIs of multiple ICRs are aberrantly
methylated in both human PSCs and pediatric cancers.
However, we also identified that adult cancers exhibit
distinct patterns of CGI hypermethylation from iPSCs;
adult cancers display genome-wide global CGI hyperme-
thylation while iPSCs exhibit ICR-preferred CGI hyperme-
thylation. Notably, in sharp contrast to adult cancers, pedi-
atric cancers did not show global CGI hypermethylation
but exhibited ICR-preferred CGI hypermethylation, indi-
cating that pediatric cancers harbor shared aberrant epige-
netic signatures with human PSCs. A recent study demon-
strated that CGI hypermethylation in adult cancers is
associated with activated fibroblast growth factor (FGF)
signaling (Smith et al., 2017). The fact that pediatric can-
cers infrequently harbor genetic aberrations in compo-
nents of the FGF pathway might explain the absence of
global CGI in pediatric cancers. Collectively, these findings
highlighted the unique patterns of epigenetic aberrations
in pediatric cancers, which exhibit differences from adult
cancers but similarities with iPSCs. Considering that the
premature termination of in vivo reprogramming causes
pediatric cancer-like tumors in mice (Ohnishi et al., 2014)
and that pediatric cancers harbor PSC-like transcriptional
signatures (Terada et al., 2019), these results raised the
possibility that some aspects of reprogramming to PSCs
may drive the development of pediatric cancers with
concomitant aberrations in ICR methylation.
Figure 6. Pediatric Cancers Exhibit Hypermethylation at ICRs but Not at Global CGIs
(A) Heatmap for DNA methylation levels at imprinted DMRs in human normal kidney samples, renal cell carcinomas (RCC), and Wilms’
tumors. Color scale is shown for DNAmethylation levels. Infinium 450K data of normal kidney tissues andWilms’ tumors were obtained from
GEO: GSE59157. Those of RCCs were obtained from GEO: GSE70303.
(B) Box plots of DNA methylation levels at representative hypermethylated imprinted DMRs in Wilms’ tumors. Solid lines in each box
indicate the median. The bottom and top of the boxes are lower and upper quartiles, respectively. Whiskers extend to ±1.5 IQR. Note that
H19 DMR and RB1 DMR are hypermethylated in Wilms’ tumor but not in normal kidney or RCC. ****p < 0.0001 (Mann-Whitney U test).
(C) Box plot of DNA methylation levels at all CGIs in normal tissues, pediatric cancers, adult cancers, somatic cells, and PSCs. Solid lines in
each box indicate the median. The bottom and top of the boxes are lower and upper quartiles, respectively. Whiskers extend to ±1.5 IQR.
Note that increased CGI methylation is observed in adult cancers but not in pediatric cancers. Data of somatic cells and PSCs are the same
as in Figure 4A.
(D) Hierarchical clustering analysis based on the methylation status at all CGIs.
(E) Box plot of DNA methylation levels at CGIs linked to PcG target genes (Lee et al., 2006) in normal tissues, pediatric cancers, adult
cancers, somatic cells, and PSCs. Solid lines in each box indicate the median. The bottom and top of the boxes are lower and upper
quartiles, respectively. Whiskers extend to ±1.5 IQR.
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To conclude, our findings about de novoCGImethylation
may provide important insights into the faithful recapitu-
lation of in vivo pluripotent cells in vitro. Our findings
may also underscore the significant relevance of reprog-
ramming-associated epigenetic aberrations in the develop-
ment of pediatric cancers.
EXPERIMENTAL PROCEDURES
Detailed descriptions of experimental procedures can be found in
Supplemental Information.
Establishment and Culture of Male ESCs and EpiSCs
Zygotes with an (129X1/SvJ 3 MSM/Ms) F1 genetic background
were obtained by in vitro fertilization (IVF). ESCs established in a
previous studywere used in this study (Yagi et al., 2017a). Epiblasts
were divided from the extraembryonic regions and transferred into
culture plates to derive EpiSCs.
Generation and Culture of Male iPSCs and iEpiSCs
Dox-inducible PB vector containing tetO-Oct4-Sox2-Klf4-cMyc-
IRES-mCherry-EF1-rtTA-IRES-Neo (PB-OSKM) was used for reprog-
ramming. After transfection, cultured medium was switched to
ESC medium containing 2 mg/mL Dox (Sigma) for iPSC derivation
and iEpiSC medium for iEpiSC derivation.
Generation of iPSCs and iEpiSCs from Dnmt3a-
Deficient MEFs
Dnmt3aWTand KO MEFs were obtained by crossing Dnmt3a het-
ero KO (B6; 129S4-Dnmt3a <tm1Enl>) mice (Okano et al., 1999).
Dnmt3a WT and KO iEpiSCs were generated by Dox-inducible
PB-OSKM. Dnmt3aWTand KO iPSCs were generated in a previous
study (Stadtfeld et al., 2012).
Animals
All experiments using animals were performed under the
ethical guidelines of Kyoto University, University of Tokyo, and
Kumamoto University. MSM/Ms were obtained from RIKEN Bio
Resource Center (Takada et al., 2013, 2015).
Generation and Culture of hiPSCs
For generation of human iPSCs (hiPSCs), human peripheral blood
mononuclear cells (Cellular Technology) were cultured. After trans-
duction of the plasmidmixture (pCXLE-hOCT3/4-shp53-F, pCXLE-
hUL, pCXWB-EBNA1, andpCXLE-hSK encoding shorthairpinRNA
for DNMT3A), the cells were seeded on a 6-well plate coated with
iMatrix-511 (Takara) and cultured until hiPSC colony formation.
The selected hiPSCs were expanded in StemFit AK02N (Takara).
Library Preparation
Library preparation was performed with SureSelect Mouse
Methyl-Seq Reagent Kit (Agilent Technologies). DNA was bisul-
fite-treated using the EZ DNA Methylation-Gold Kit. The libraries
were then sequenced on HiSeq 2500 (2 3 100-bp or 2 3 101-bp
paired-end reads, Illumina). RNA-seq libraries were generated
using the Truseq Stranded mRNA LT sample prep kit (Illumina).
RNA-seq libraries were sequenced on NextSeq500 (75-bp single
read, Illumina).
DNA Methylation Analyses
For allelicmethylation analyses, the SNPdata forMSM/Mswere ob-
tained from NIG Mouse Genome Database (MSMv4HQ, http://
molossinus.lab.nig.ac.jp/msmdb/index.jsp). The B6-derived and
MSM/Ms-derived sequenced reads were determined based on the
MSM/Ms SNP data. Previously described mouse CGIs (Illingworth
et al., 2010) and mouse ICRs (Court et al., 2014; Tomizawa et al.,
2011) were used for CGI and imprinting analyses, respectively. In-
finium array data were obtained from publicly available datasets.
Previously describedhumanCGIs (Illingworth et al., 2010), human
ICRs (Court et al., 2014; Tomizawa et al., 2011), and PcG target
genes (Lee et al., 2006) were used for methylation analyses. The
average methylation signals of each ICR were used for comparison
among samples.
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